TY - JOUR
T1 - Clinically significant pocket hematoma increases long-term risk of device infection
T2 - BRUISE CONTROL INFECTION study
AU - BRUISE CONTROL Investigators
AU - Essebag, Vidal
AU - Verma, Atul
AU - Healey, Jeff S.
AU - Krahn, Andrew D.
AU - Kalfon, Eli
AU - Coutu, Benoit
AU - Ayala-Paredes, Felix
AU - Tang, Anthony S.
AU - Sapp, John
AU - Sturmer, Marcio
AU - Keren, Arieh
AU - Wells, George A.
AU - Birnie, David H.
AU - Green, Martin
AU - Nery, Pablo
AU - Lemery, Robert
AU - Gollob, Michael
AU - Davis, Darryl
AU - Redpath, Calum
AU - Duchesne, Lloyd
AU - Carlin, Leslie
AU - MacDonald, Karen
AU - Dunne, Rosemary
AU - Fleming, Rochelle
AU - Yeltsir, Elizabeth
AU - Chen, Li
AU - Tran, My Linh
AU - Coyle, Doug
AU - Hadjis, Tomy
AU - Bernier, Martin L.
AU - Omelchenko, Alexander
AU - Rafti, Fiorella
AU - Beaudoin, Johannie
AU - Bureau, Johanne
AU - Coutu, Isabelle
AU - Vaillancourt, Emilie
AU - Manlucu, Jaimie
AU - Yee, Raymond
AU - Skanes, Allan
AU - Gula, Lorne
AU - Klein, George
AU - Leong-Sit, Peter
AU - Nyman, Lynn
AU - Bentley, Cathy
AU - Hulley, Denise
AU - Morillo, Carlos
AU - Connolly, Stuart
AU - Nair, Girish
AU - Divakaramenon, S.
AU - Laish-Farkash, Avishag
N1 - Funding Information:
Supported by an operating grant from the Canadian Institutes of Health Research (CIHR), a CIHR Clinician Scientist Award (to Dr. Essebag) and an Innovations grant from the University of Ottawa Heart Institute Academic Medical Organization Alternate Funding Program (funded by the Ministry of Health of Ontario). Dr. Coutu is a consultant for Bayer. Dr. Sapp is a consultant for Biosense Webster; and receives research funding from Biosense Webster and Philips Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Essebag and Birnie were coprincipal investigators and contributed equally to this work.
Publisher Copyright:
© 2016 American College of Cardiology Foundation.
PY - 2016/3/22
Y1 - 2016/3/22
N2 - Background The BRUISE CONTROL trial (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial) demonstrated that a strategy of continued warfarin during cardiac implantable electronic device surgery was safe and reduced the incidence of clinically significant pocket hematoma (CSH). CSH was defined as a post-procedure hematoma requiring further surgery and/or resulting in prolongation of hospitalization of at least 24 h, and/or requiring interruption of anticoagulation. Previous studies have inconsistently associated hematoma with the subsequent development of device infection; reasons include the retrospective nature of many studies, lack of endpoint adjudication, and differing subjective definitions of hematoma. Objectives The BRUISE CONTROL INFECTION (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial Extended Follow-Up for Infection) prospectively examined the association between CSH and subsequent device infection. Methods The study included 659 patients with a primary outcome of device-related infection requiring hospitalization, defined as 1 or more of the following: pocket infection; endocarditis; and bloodstream infection. Outcomes were verified by a blinded adjudication committee. Multivariable analysis was performed to identify predictors of infection. Results The overall 1-year device-related infection rate was 2.4% (16 of 659). Infection occurred in 11% of patients (7 of 66) with previous CSH and in 1.5% (9 of 593) without CSH. CSH was the only independent predictor and was associated with a >7-fold increased risk of infection (hazard ratio: 7.7; 95% confidence interval: 2.9 to 20.5; p < 0.0001). Empiric antibiotics upon development of hematoma did not reduce long-term infection risk. Conclusions CSH is associated with a significantly increased risk of infection requiring hospitalization within 1 year following cardiac implantable electronic device surgery. Strategies aimed at reducing hematomas may decrease the long-term risk of infection.
AB - Background The BRUISE CONTROL trial (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial) demonstrated that a strategy of continued warfarin during cardiac implantable electronic device surgery was safe and reduced the incidence of clinically significant pocket hematoma (CSH). CSH was defined as a post-procedure hematoma requiring further surgery and/or resulting in prolongation of hospitalization of at least 24 h, and/or requiring interruption of anticoagulation. Previous studies have inconsistently associated hematoma with the subsequent development of device infection; reasons include the retrospective nature of many studies, lack of endpoint adjudication, and differing subjective definitions of hematoma. Objectives The BRUISE CONTROL INFECTION (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial Extended Follow-Up for Infection) prospectively examined the association between CSH and subsequent device infection. Methods The study included 659 patients with a primary outcome of device-related infection requiring hospitalization, defined as 1 or more of the following: pocket infection; endocarditis; and bloodstream infection. Outcomes were verified by a blinded adjudication committee. Multivariable analysis was performed to identify predictors of infection. Results The overall 1-year device-related infection rate was 2.4% (16 of 659). Infection occurred in 11% of patients (7 of 66) with previous CSH and in 1.5% (9 of 593) without CSH. CSH was the only independent predictor and was associated with a >7-fold increased risk of infection (hazard ratio: 7.7; 95% confidence interval: 2.9 to 20.5; p < 0.0001). Empiric antibiotics upon development of hematoma did not reduce long-term infection risk. Conclusions CSH is associated with a significantly increased risk of infection requiring hospitalization within 1 year following cardiac implantable electronic device surgery. Strategies aimed at reducing hematomas may decrease the long-term risk of infection.
KW - anticoagulants
KW - hemorrhage
KW - infection
KW - risk factors
UR - http://www.scopus.com/inward/record.url?scp=84962921637&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2016.01.009
DO - 10.1016/j.jacc.2016.01.009
M3 - Article
C2 - 26988951
AN - SCOPUS:84962921637
SN - 0735-1097
VL - 67
SP - 1300
EP - 1308
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 11
ER -